{"id":654295,"date":"2023-06-05T20:32:01","date_gmt":"2023-06-05T20:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=654295"},"modified":"2023-06-05T20:32:01","modified_gmt":"2023-06-05T20:32:01","slug":"technology-update-digital-therapeutic-dtx-market-size-top-companies-analysis-and-advancements-till-2027","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/technology-update-digital-therapeutic-dtx-market-size-top-companies-analysis-and-advancements-till-2027_654295.html","title":{"rendered":"Technology Update: Digital Therapeutic (DTx) Market Size, Top Companies Analysis, and Advancements till 2027"},"content":{"rendered":"
\n
\"Technology<\/a><\/div>\n
\n
Prominent players in the digital therapeutics market include Noom (US), Livongo Health (US), Omada Health (US), WellDoc (US), Pear Therapeutics (US), Proteus Digital Health (US), Propeller Health (US), Akili Interactive Labs (US), Better Therapeutics (US),<\/div>\n<\/div>\n<\/div>\n
The Growth in this DTx market is primarily driven by the increasing incidence of preventable chronic diseases, the need to control healthcare costs, rising focus on preventive healthcare, and rising investments in digital therapeutics<\/div>\n

According to the new market research report “<\/strong>Digital Therapeutics (DTx) Market<\/a> by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel (B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma) – Global Forecasts to 2026″,<\/strong> published by MarketsandMarkets™, the Global DTx Market is projected to reach USD 13.1 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 31.4% during the forecast period.<\/p>\n

The growth of the digital therapeutics market is primarily driven by factors such as government initiatives for preventive healthcare, technological advancements in mobile healthcare, a significant increase in venture capital investments, and the benefits of digital therapeutics, such as the ability to induce behavioral change (an important challenge in healthcare), user-friendliness, patient convenience, and improved drug compliance.<\/p>\n

Request Sample Pages: https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=51646724<\/a><\/strong><\/p>\n

North America commanded the largest share of the digital therapeutics market<\/strong><\/p>\n

North America held the largest share of the DTx Market, followed by Europe. The market in North America is also expected to grow at the highest CAGR of 32.2%. Factors such as the influx of new start-ups, increasing investments in digital therapeutics, improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements drive market growth in this region.<\/p>\n

Market Dynamics<\/strong><\/p>\n

1. Increasing incidence of preventable chronic diseases<\/p>\n

2. Rising focus on preventive healthcare<\/p>\n

3. Need to control healthcare costs<\/p>\n

4. Significant increase in venture capital investments<\/p>\n

5. Benefits of digital therapeutics<\/strong> : Ability to induce behavioral change, Improved drug adherence & Patient convenience and user-friendliness<\/p>\n

The Digital Therapeutics market is fragmented with the presence of emerging players;<\/strong><\/p>\n

Noom (US), Livongo Health (US), Omada Health (US), WellDoc (US), Pear Therapeutics (US), Proteus Digital Health (US), Propeller Health (US), Akili Interactive Labs (US), Better Therapeutics (US), Happify (US), Kaia Health (Germany), Mango Health (US), Click Therapeutics (US), Canary Health (US), Wellthy Therapeutics (India), Cognoa (US), CogniFit (US), Ayogo Health (Canada), Mindstrong Health (US), 2Morrow (US), and Ginger (US).<\/strong><\/p>\n

Speak to Analyst: https:\/\/www.marketsandmarkets.com\/speaktoanalystNew.asp?id=51646724<\/a><\/strong><\/p>\n

Digital Therapeutics Market, by Sales Channel<\/strong><\/p>\n